Marex Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marex Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-74,314	Closed	-$4.42M	–	1039
2025 Q4	$4.42M	Buy	74,314 +47,824	+181%	+$2.6M	0.03%	230
2025 Q3	$1.43M	Buy	26,490 +12,762	+93%	+$730K	0.01%	298
2025 Q2	$755K	Buy	+13,728	New	+$808K	0.01%	322
2024 Q2	–	Sell	-7,778	Closed	-$679K	–	639
2024 Q1	$679K	Buy	7,778 +3,709	+91%	+$332K	0.02%	217
2023 Q4	$392K	Sell	4,069 -3,952	-49%	-$350K	0.02%	344
2023 Q3	$710K	Sell	8,021 -3,462	-30%	-$308K	0.1%	91
2023 Q2	$995K	Buy	+11,483	New	+$1.08M	0.18%	91
2023 Q1	–	Sell	-4,339	Closed	-$449K	–	265
2022 Q4	$449K	Buy	+4,339	New	+$407K	0.06%	179

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group's BMRN Position: Q1 2026 in Review

Marex Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 74,314 shares — an estimated $4.42M sold.

Marex Group first reported a position in BMRN in Q4 2022 and held it in 8 quarters. The position peaked at $4.42M in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Marex Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Marex Group sold 74,314 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.42M.
Marex Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 8 quarters.
Marex Group's BioMarin Pharmaceuticals position peaked at $4.42M in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.